Streptozotocin-Induced Diabetic Models in Mice and Rats

Current Protocols in Pharmacology

Volumn 70, Issue 1, 2015, Pages 5.47.1-5.47.20

  Furman, Brian L ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

high fat; hyperglycemia; insulin deficiency; insulin resistance; insulitis; mouse or rat; nicotinamide; streptozotocin; type 1 diabetes mellitus; type 2 diabetes mellitus

Indexed keywords

GLUCOSE; NICOTINAMIDE; STREPTOZOCIN; INSULIN;

ARTICLE; BLOOD GLUCOSE MONITORING; C57BL 6 MOUSE; CD-1 MOUSE; CLINICAL PROTOCOL; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; RAT MODEL; SPRAGUE DAWLEY RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DIABETES MELLITUS, EXPERIMENTAL; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; LIPID DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; WISTAR RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERGLYCEMIA; INJECTIONS, INTRAPERITONEAL; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; NIACINAMIDE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; STREPTOZOCIN;

EID: 84963675332     PISSN: 19348282     EISSN: 19348290     Source Type: Journal    
DOI: 10.1002/0471141755.ph0547s70     Document Type: Article

References (45)

1. Arison, R.N, Ciaccio, E.I, Glitzer, M.S, Cassaro, J.A, and Pruss, M.P. 1967. Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin. Diabetes 16:51-56.
2. Bond, J.S, Failla, M.L, and Unger, D.F. 1983. Elevated manganese concentration and arginase activity in livers of streptozotocin-induced diabetic rats. J. Biol. Chem. 258:8004-8009.
3. Bonnevie-Nielsen, V, Steffes, M.W, and Lernmark, A. 1981. A major loss in islet mass and B-cell function precedes hyperglycemia in mice given multiple low doses of streptozotocin. Diabetes 30:424-429.
4. Breyer, M.D, Bottinger, E, Brosius, F.C. 3rd, Coffman, T.M, Harris, R.C, Heilig, C.W, and Sharma, K, AMDCC. 2005. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 16:27-45.
5. Brondum, E, Nilsson, H, and Aalkjaer, C. 2005. Functional abnormalities in isolated arteries from Goto-Kakizaki and streptozotocin-treated diabetic rat models. Horm. Metab. Res. 37:56-60.
6. Byrne, F.M, Cheetham, S, Vickers, S, and Chapman, V. 2015. Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments. J. Diabetes Res. 2015:752481.
7. Chan, P, Wong, K.L, Liu, I.M, Tzeng, T.F, Yang, T.L, and Cheng, J.T. 2003. Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats. J. Hypertens. 21:761-769.
8. Deeds, M.C, Anderson, J.M, Armstrong, A.S, Gastineau, D.A, Hiddinga, H.J, Jahangir, A, Eberhardt, N.L, and Kudva, Y.C. 2011. Single dose streptozotocin induced diabetes: Considerations for study design in islet transplantation models. Lab Anim. 45:131-140.
9. Donovan, J. and Brown, P. 1998. Anesthesia. Curr. Protoc. Immunol. 27:1.4.1-1.4.5.
10. Donovan, J. and Brown, P. 2006a. Parenteral injections. Curr. Protoc. Immunol. 73:1.6.1-1.6.10.
11. Donovan, J. and Brown, P. 2006b. Blood collection. Curr. Protoc. Immunol. 73:1.7.1-1.7.9.
12. Flood, J.F, Mooradian, A.D, and Morley, J.E. 1990. Characteristics of learning and memory in streptozotocin-induced diabetic mice. Diabetes 39:1391-1398.
13. Ganda, O.P, Rossini, A.A, and Like, A.A. 1976. Studies on streptozotocin diabetes. Diabetes 25:595-603.
14. Ghasemi, M, Shafroodi, H, Gholipour, T, Nezami, B. G, Ebrahimi, F, and Dehpour, A.R. 2010. ATP-sensitive potassium channels contribute to the time-dependent alteration in pentylenetetrazole-induced seizure threshold in diabetic mice. Seizure 19:53-58.
15. Ghasemi, A, Khalifi, S, and Jedi, S.S. 2014. Streptozotocin-nicotinamide-induced rat model of type 2 diabetes. Acta Physiol. Hungarica 101:408-420.
16. Hartnell, J.M, Storrie, M.C, and Mooradian, A.D. 1990. Diabetes-related changes in chromatin structure of brain, liver, and intestinal epithelium. Diabetes 39:348-353.
17. Huang, F. and Wu, W. 2005. Antidiabetic effect of a new peptide from Squalus mitsukurii liver (S-8300) in streptozocin-induced diabetic mice. J. Pharm. Pharmacol. 57:1575-1580.
18. Junod, A, Lambert, A.E, Stauffacher, W, and Renold, A.E. 1969. Diabetogenic action of streptozotocin: Relationship of dose to metabolic response. J. Clin. Invest. 48:2129-2139.
19. Junod, A, Lambert, A.E, Orci, L, Pictet, R, Gonet, A.E, and Renold, A.E. 1967. Studies of the diabetogenic action of streptozotocin. Proc. Soc. Exp. Biol. Med. 126:201-205.
20. Kolb, H. 1987. Mouse models of insulin dependent diabetes: Low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes Metab. Rev. 3:751-778.
21. Kolb-Bachofen, V, Epstein, S, Kiesel, U, and Kolb, H. 1988. Low-dose streptozocin-induced diabetes in mice. Electron microscopy reveals single-cell insulitis before diabetes onset. Diabetes 37:21-27.
22. Kunjathoor, V.V, Wilson, D.L, and LeBoeuf, R.C. 1996. Increased atherosclerosis in streptozotocin-induced diabetic mice. J. Clin. Invest. 97:1767-1773.
23. Lazar, M, Golden, P, Furman, M, and Lieberman, T.W. 1968. Resistance of the rabbit to streptozocin. Lancet 26:919.
24. Like, A.A. and Rossini, A.A. 1976. Streptozotocin-induced pancreatic insulitis: New model of diabetes mellitus. Science 193:415-417.
25. Lin, M, Yin, N, Murphy, B, Medof, M.E, Segerer, S, Heeger, P.S, and Schröppel, B. 2010. Immune cell-derived c3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin. Diabetes 59:2247-2252.
26. Luo, P, Zhou, Y, Chang, H.H, Zhang, J, Seki, T, Wang, C.Y, Inscho, E.W, and Wang, M.H. 2009. Glomerular 20-HETE, EETs, and TGF-beta1 in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 96:F556-F563.
27. Mabley, J.G, Rabinovitch, A, Suarez-Pinzon, W, Haskó, G, Pacher, P, Power, R, Southan, G, Salzman, A, and Szabó, C. 2003. Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes. Mol. Med. 9:96-104.
28. Mancini, J.E, Ortiz, G, Croxatto, J.O. and Gallo, J.E. 2013. Retinal upregulation of inflammatory and proangiogenic markers in a model of neonatal diabetic rats fed on a high-fat-diet. BMC Ophthalmol. 13:14.
29. Masiello, P. 2006. Animal models of type 2 diabetes with reduced pancreatic beta-cell mass. Int. J. Biochem. Cell Biol. 38:873-893.
30. Masiello, P, Broca, C, Gross, R, Roye, M, Manteghetti, M, Hillaire-Buys, D, Novelli, M, and Ribes, G. 1998. Experimental NIDDM: Development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 47:224-229.
31. Paik, S.G, Michelis, M.A, Kim, Y.T, and Shin, S. 1982. Induction of insulin-dependent diabetes by streptozotocin. Inhibition by estrogens and potentiation by androgens. Diabetes 31:724-729.
32. Rakieten, N, Rakieten, M.L, and Nadkarni, M.V. 1963. Studies on the diabetogenic action of streptozotocin. Cancer Chemother. Rep. 29:91.
33. Reed, M.J, Meszaros, K, Entes, L.J, Claypool, M.D, Pinkett, J.G, Gadbois, T.M, and Reaven, G.M. 2000. A new rat model of type 2 diabetes: The fat-fed, streptozotocin-treated rat. Metabolism 49:1390-1394.
34. Rossini, A.A, Appel, M.C, Williams, R.M, and Like, A.A. 1977. Genetic influence of the streptozotocin-induced insulitis and hyperglycemia. Diabetes 26:916-920.
35. Schein, P.S, Cooney, D.A, and Vernon M.L. 1967. The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. Cancer Res. 27:2324-2332.
36. Skovso, S. 2014. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J. Diabetes Invest. 5:349-358.
37. Usuki, S, Ito, Y, Morikawa, K, Kise, M, Ariga, T, Rivner, M, and Yu, R.K. 2007. Effect of pregerminated brown rice intake on diabetic neuropathy in streptozotocin-induced diabetic rats. Nutr. Metab. 4:25.
38. Vital, P, Larrieta, E, and Hiriart, M. 2006. Sexual dimorphism in insulin sensitivity and susceptibility to develop diabetes in rats. J. Endocrinol. 190:425-432.
39. Wang, B, Chandrasekera, P.C, and Pippin, J.J. 2014. Leptin- and leptin receptor-deficient rodent models: Relevance for human type 2 diabetes. Curr. Diabetes Rev. 10:131-145.
40. Weide, L.G. and Lacy, P.E. 1991. Low-dose streptozocin-induced autoimmune diabetes in islet transplantation model. Diabetes 40:1157-1162.
41. Wu, K.K. and Huan, Y. 2007. Diabetic atherosclerosis mouse models. Atherosclerosis 191:241-249.
42. Yin, D, Tao, J, Lee, D.D, Shen, J, Hara, M, Lopez, J, Kuznetsov, A, Philipson, L.H, and Chong, A.S. 2006. Recovery of islet beta-cell function in streptozotocin-induced diabetic mice: An indirect role for the spleen. Diabetes 55:3256-3263.
43. Zhang, M, Lv, X.Y, Li, J, Xu, Z.G, and Chen, L. 2008. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp. Diabetes Res. 2008:704045.
44. Zunino, S.J, Simons, L.F, Sambrook, J.F, and Gething, M.J. 1994. Interleukin-1 promotes hyperglycemia and insulitis in mice normally resistant to streptozotocin-induced diabetes. Am. J. Pathol. 145:661-670.
45. http://www.AMDCC.org